Search

Displaying results 5281 - 5290 of 10000 in total
  1. Drug

    Parsaclisib

    go.drugbank.com/drugs/DB14867
    Investigational

    Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).

  2. Drug

    Narazaciclib

    go.drugbank.com/drugs/DB19038
    Investigational

    Narazaciclib is under investigation in clinical trial NCT06351644 (On 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed And/or Refractory Multiple Myeloma).

  3. Drug

    JNJ-42165279

    go.drugbank.com/drugs/DB15173
    Investigational

    Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).

  4. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease).

  5. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system.

  6. Drug

    Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10774
    ApprovedInvestigationalWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  7. Drug

    Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10775
    ApprovedInvestigationalWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  8. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10792
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Influenza A virus A/Bolivia/559/2013 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB11034
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB11035
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.